Aura Biosciences (NASDAQ:AURA) Given New $23.00 Price Target at JMP Securities

Aura Biosciences (NASDAQ:AURA) had its price objective hoisted by JMP Securities from $19.00 to $23.00 in a research report report published on Friday morning, Benzinga reports. They currently have a market outperform rating on the stock.

AURA has been the topic of several other research reports. Lifesci Capital upgraded Aura Biosciences to a strong-buy rating in a report on Monday, September 9th. HC Wainwright began coverage on shares of Aura Biosciences in a research report on Thursday, July 25th. They issued a buy rating and a $21.00 target price on the stock.

Aura Biosciences Stock Performance

Aura Biosciences stock opened at $10.07 on Friday. The firm has a market cap of $499.57 million, a price-to-earnings ratio of -5.41 and a beta of 0.35. Aura Biosciences has a 1 year low of $5.99 and a 1 year high of $12.35. The firm’s 50 day moving average price is $8.52 and its two-hundred day moving average price is $7.88.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.04. As a group, equities analysts predict that Aura Biosciences will post -1.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Monashee Investment Management LLC purchased a new position in Aura Biosciences during the 4th quarter valued at about $1,758,000. Franklin Resources Inc. purchased a new position in Aura Biosciences during the fourth quarter valued at approximately $5,317,000. Platinum Investment Management Ltd. purchased a new position in Aura Biosciences during the fourth quarter valued at approximately $1,596,000. Levin Capital Strategies L.P. increased its stake in Aura Biosciences by 194.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock valued at $2,476,000 after buying an additional 216,266 shares during the period. Finally, Matrix Capital Management Company LP lifted its position in Aura Biosciences by 29.1% in the 4th quarter. Matrix Capital Management Company LP now owns 6,922,870 shares of the company’s stock worth $61,337,000 after buying an additional 1,560,000 shares in the last quarter. 96.75% of the stock is owned by institutional investors and hedge funds.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.